DE LUCA, Giovanna
 Distribuzione geografica
Continente #
NA - Nord America 2.396
EU - Europa 2.156
AS - Asia 983
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 1
Totale 5.545
Nazione #
US - Stati Uniti d'America 2.392
CN - Cina 506
IE - Irlanda 458
UA - Ucraina 451
GB - Regno Unito 337
TR - Turchia 332
SE - Svezia 282
IT - Italia 178
FR - Francia 177
DE - Germania 139
IN - India 91
FI - Finlandia 87
VN - Vietnam 33
BE - Belgio 25
IR - Iran 10
EU - Europa 9
RU - Federazione Russa 7
PL - Polonia 6
IL - Israele 5
GR - Grecia 4
CA - Canada 3
KR - Corea 3
AM - Armenia 1
AT - Austria 1
BG - Bulgaria 1
DK - Danimarca 1
EG - Egitto 1
HK - Hong Kong 1
IM - Isola di Man 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
Totale 5.545
Città #
Chandler 517
Jacksonville 517
Dublin 454
Southend 260
Izmir 193
Princeton 190
Nanjing 153
Wilmington 129
Ashburn 106
Beijing 95
Dearborn 90
Cambridge 85
Nanchang 59
Woodbridge 53
Ann Arbor 52
Altamura 46
New York 42
Chieti 34
Dong Ket 33
Jiaxing 29
Houston 28
Shenyang 26
Norwalk 25
Brussels 24
Boardman 22
Kunming 20
Grevenbroich 19
Tianjin 19
Hebei 16
Washington 15
Hangzhou 13
Changsha 12
Leawood 12
San Mateo 12
Ardabil 10
Augusta 9
Cedar Knolls 9
Jinan 9
Torino 9
Campobasso 7
Lanzhou 7
Monmouth Junction 7
Falls Church 6
Guangzhou 6
Kraków 6
London 6
Ningbo 6
Changchun 5
Hanover 5
Helsinki 5
Orange 5
Taizhou 5
Zhengzhou 5
San Vito Chietino 4
Borgomanero 3
Florence 3
Los Angeles 3
Mumbai 3
Oxford 3
Pescara 3
Pianella 3
Tappahannock 3
Teramo 3
Toronto 3
Walnut 3
Auburn Hills 2
Bangalore 2
Benevento 2
Cedar Lake 2
Düsseldorf 2
Frankfurt am Main 2
Fuzhou 2
Hefei 2
Isernia 2
Naples 2
Phoenix 2
Rome 2
Seattle 2
Shanghai 2
Somerville 2
Stockholm 2
Andover 1
Antwerp 1
Archi 1
Basking Ridge 1
Berlin 1
Boston 1
Cairo 1
Candiolo 1
Central 1
Chengdu 1
Domusnovas 1
Douglas 1
Fairfield 1
Gandhi Nagar 1
Glasgow 1
Haikou 1
Hyderabad 1
Iasi 1
Islington 1
Totale 3.615
Nome #
IL 13 in multiple sclerosis 113
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 105
Proteomic investigations on differential post-translational modifications of transthyretin in multiple sclerosis 94
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 89
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 88
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 85
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 82
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 79
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 79
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 79
Effect of TNF intraneural injection into the rat sciatic nerve 78
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 78
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 77
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 77
Increasing age at disability milestones among MS patients in the MSBase Registry 76
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 76
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 75
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 74
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 74
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 74
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 73
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 72
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 72
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 71
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 70
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 70
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 70
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 69
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 69
Nail loss after teriflunomide treatment: a new potential adverse event 69
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 68
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 68
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 67
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 67
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 66
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 66
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 66
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 65
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 65
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 65
Interferon beta1b: the Chieti experience 64
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 64
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 64
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 64
Effect of rhTNF-alpha injection into rat sciatic nerve 63
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 63
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 62
Effect of rhTNF-a injection into rat sciatic nerve 62
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 62
JCV-Ab serostatus in MS patients treated with Natalizumab 62
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 62
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 61
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 60
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 60
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 59
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 59
Mononeuropathy following subcutaneous interferon-β injection 59
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 59
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 58
Interferone beta1b: bilancio su un gruppo di 30 pazienti 57
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 57
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 57
Interferon β 1b: The Chieti experience 57
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 56
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 55
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 54
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 54
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 53
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 53
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 53
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 52
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 50
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 49
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 49
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 48
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 47
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 46
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 43
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 41
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 41
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 40
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 40
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 34
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 34
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 32
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 31
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 30
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 29
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 28
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 28
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 26
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 21
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 14
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 13
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 12
Totale 5.671
Categoria #
all - tutte 16.796
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.796


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019262 0 0 0 0 0 0 0 7 6 3 2 244
2019/20201.112 353 83 7 34 68 95 121 105 17 90 135 4
2020/2021619 87 0 92 1 37 124 1 2 80 68 58 69
2021/2022362 2 4 6 60 11 11 16 34 32 7 55 124
2022/20231.368 105 155 73 160 149 275 98 102 175 17 29 30
2023/2024577 47 36 39 16 42 228 147 22 0 0 0 0
Totale 5.671